Based on our previous analysis of ex vivo drug response patterns in AML patients, where receptor-type tyrosine-protein kinase FLT3 internal tandem duplication (FLT3-ITD) mutation status was found to be associated with functional classification of the AML subtypes (Pemovska et al., 2013), here we focused specifically on the FTL3-ITD addiction levels across the leukemia patient samples. The gene discussed is FLT3; the disease is leukemia.